Kamada Stock Forecast, Price & News

-0.03 (-0.56 %)
(As of 09/17/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume19,226 shs
Average Volume118,874 shs
Market Capitalization$239.07 million
P/E Ratio19.89
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

Kamada logo

About Kamada

Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the following segments: Proprietary Products and Distribution. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.33 out of 5 stars

Medical Sector

1101st out of 1,351 stocks

Pharmaceutical Preparations Industry

535th out of 664 stocks

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Kamada (NASDAQ:KMDA) Frequently Asked Questions

What stocks does MarketBeat like better than Kamada?

Wall Street analysts have given Kamada a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kamada wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kamada's next earnings date?

Kamada is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for Kamada

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) released its earnings results on Wednesday, August, 11th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.05 by $0.03. Kamada had a trailing twelve-month return on equity of 6.73% and a net margin of 10.42%.
View Kamada's earnings history

How has Kamada's stock price been impacted by Coronavirus?

Kamada's stock was trading at $5.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KMDA shares have increased by 4.3% and is now trading at $5.37.
View which stocks have been most impacted by COVID-19

Who are Kamada's key executives?

Kamada's management team includes the following people:
  • Amir London, Chief Executive Officer
  • Eran Nir, Vice President-Operations
  • Chaime Orlev, Chief Financial Officer
  • Naveh Tov, VP-Clinical Development & Medical Director
  • Michal Ayalon, Vice President-Research & Development

Who are some of Kamada's key competitors?

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by a variety of institutional and retail investors. Top institutional investors include Jefferies Group LLC (0.00%), Renaissance Technologies LLC (2.52%), ARK Investment Management LLC (2.06%), Vanguard Group Inc. (1.70%), Jefferies Group LLC (0.00%) and Group One Trading L.P. (0.00%).

Which major investors are selling Kamada stock?

KMDA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and JPMorgan Chase & Co..

Which major investors are buying Kamada stock?

KMDA stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Jefferies Group LLC, Group One Trading L.P., SG3 Management LLC, Wolverine Trading LLC, Cutler Group LP, ARK Investment Management LLC, and Seizert Capital Partners LLC.

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.37.

How much money does Kamada make?

Kamada has a market capitalization of $239.07 million and generates $133.25 million in revenue each year. The biotechnology company earns $17.14 million in net income (profit) each year or $0.38 on an earnings per share basis.

How many employees does Kamada have?

Kamada employs 408 workers across the globe.

What is Kamada's official website?

The official website for Kamada is

Where are Kamada's headquarters?

Kamada is headquartered at 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at (728) 940-6472 or via email at [email protected]

This page was last updated on 9/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.